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Abstract: Even with the introduction of targeted agents and the
establishment of multiple lines of therapy, the median survival for
patients with advanced non-small cell lung cancer (NSCLC) does
not considerably extend beyond 1 year. Emerging research suggests
that clinical characteristics alone are insufficient for selecting pa-
tients for therapies that may confer significant survival benefit. The
discovery of predictive and prognostic molecular markers such as
gene mutations in EGFR and KRAS as well as high tumor expression
levels of DNA repair pathway components ribonucleotide reductase
subunit 1 and excision repair cross-complementing group 1 has
sparked an interest in the development of individualized therapy as
a strategy for increasing survival in patients with NSCLC. Tech-
niques to analyze molecular biomarkers, such as immunohistochem-
istry, fluorescence in situ hybridization, polymerase chain reaction,
and, more recently, gene microarray techniques, are being investi-
gated for their potential to accurately predict an individual patient’s
response to therapy. Many prospective trials are still needed to
clarify and confirm the utility of molecular biomarkers for guiding
treatment selection, and continued participation in clinical trials is
critical for the development of tools to provide customized treatment
plans for patients with NSCLC.
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Lung cancer is the leading cause of cancer death in theUnited States, accounting for an estimated 161,840 deaths
during 2008.1 Despite several decades of extensive research,
the median survival for patients with non-small cell lung
cancer (NSCLC) is approximately 1 year.2 Recent studies
have confirmed the efficacy of platinum doublets for the
treatment of advanced or metastatic NSCLC; however, an
efficacy plateau has been reached with existing cytotoxic
agents.3–5 To increase efficacy and reduce treatment-related
toxicities, investigators have focused on the development of
strategies to individualize therapy on the basis of tumor
molecular characteristics. Recently, molecular biomarkers
have been identified, which may be a predictive of response
to therapy or prognostic of survival. Predictive markers can
be used for therapeutic decision making, whereas prognostic
markers have the ability to estimate patient outcome inde-
pendent of treatment modality.6 On November 12, 2008, a
panel of medical and surgical oncologists convened in Chi-
cago, IL, to assess the status of molecular biomarkers in
current clinical practice. This article summarizes their discus-
sion on recent advances in biomarker development and the
present clinical applicability of predictive markers as tools for
selecting patients for chemotherapy and targeted agents.
ASSAY TECHNOLOGIES FOR MOLECULAR
BIOMARKER ANALYSIS
The advent of targeted therapy and the discovery of
potentially predictive and prognostic markers have sparked
an interest in the development of individualized therapy for
patients with NSCLC. Techniques such as immunohisto-
chemistry (IHC), fluorescence in situ hybridization (FISH),
reverse-transcription polymerase chain reaction, and microar-
rays have been used to characterize molecular biomarkers
that may indicate the likelihood of patient response to a
specific therapy.
IHC is a semiquantitative method for estimating protein
expression that can be conducted at the same time as histo-
logic classification.7 However, antibody-based detection
methods can yield inconsistent results because of variation in
antibody type, production batch, staining protocol, scoring
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method, and cutoff criteria.8 For example, in a study of the
Iressa Survival Evaluation in Lung Cancer trial, which inves-
tigated the efficacy of gefitinib versus placebo, two different
antibodies were compared for IHC detection of epidermal
growth factor receptor (EGFR) to predict survival among 736
patients; different antibody staining cutoff points were re-
quired to predict benefit from gefitinib, which suggests vari-
ations in antibody sensitivity.9
FISH detects genomic and chromosomal changes in
tissue block preparations by hybridizing labeled DNA probes
to a sample.10 Proper tissue handling and processing of FISH
samples are crucial to minimize background signal and en-
sure test accuracy, but standard protocols do not yet exist.8,10
Direct sequencing is the current standard method for
detecting gene mutations, but new techniques that provide
higher sensitivity and use smaller samples are being investi-
gated.8 Given the heterogeneity of lung tumors, it can be
difficult to determine mutation status throughout an entire
tumor, and for this reason, assay technology development is
moving toward global analysis to characterize tumor hetero-
geneity, tumor microenvironment, and individual genetic
factors that may influence disease management.
Gene expression profiles derived from microarrays may
reveal genomic signatures that more accurately predict pa-
tient outcomes or responses to therapy compared with tech-
niques based on individual gene characterization. Moreover,
advances in miniaturization and automation aid in the devel-
opment of technology such as the circulating tumor cell
(CTC) chip, a microfluidic device that can isolate rare CTCs
from whole blood (Figure 1).11 One major advantage of this
tool is that cancer cells captured against microposts on the
CTC chip maintain cell viability, and isolated cells can
undergo molecular analysis or feasible functional assays.
The integration of new technologies and molecular
markers into clinical practice will require protocol standard-
ization, marker validation, and a commitment to collect
adequate tissue. Although the platforms for molecular assays
are still in development, techniques for biomarker analysis
will be invaluable to understanding the biology and treatment
of NSCLC.
MOLECULAR PREDICTORS OF RESPONSE TO
CHEMOTHERAPY
Increased understanding in the molecular biology and
genetics of lung tumorigenesis has resulted in the identifica-
tion of genes that may be useful for clinical decision making,
which has led to investigations of using molecular markers as
a strategy to overcome the platinum-doublet chemotherapy
treatment plateau and reduce treatment-related toxicities. In
an effort to better select patients for chemotherapy, translational
researchers are examining molecular markers, including exci-
sion repair cross-complementing group 1 gene (ERCC1), ribo-
nucleotide reductase subunit 1 (RRM1), and thymidylate syn-
thase (TS), as well as gene expression profiling as tools to guide
chemotherapy selection for patients with NSCLC.12–16
Ribonucleotide Reductase Subunit 1 (RRM1)
RRM1 functions as the regulatory subunit of ribonu-
clease reductase, an enzyme that catalyzes the deoxynucle-
otide production required for DNA repair.12,17 The implica-
tion of RRM1 in the DNA repair process suggests that
differential RRM1 gene expression could influence the effi-
cacy of chemotherapeutic nucleoside analogue agents such as
gemcitabine.12 Although preliminary preclinical and clinical
evidence supports the observation that the response to gem-
citabine is inversely correlated with RRM1 gene expres-
sion,17–19 the correlation of tumoral RRM1 expression with a
statistically significant improvement in survival from chemo-
therapy has yet to be demonstrated consistently. In a retro-
spective study of a large, randomized trial investigating the
efficacy of frontline chemotherapy in 100 patients with ad-
FIGURE 1. A, SEM image of an array of microposts etched
in silicon. B, SEM image of an NCI-H1650 lung cancer cell
spiked into blood. It has been captured on a micropost that
has been chemically functionalized with antibodies against
EpCAM. Inset image shows the cell at high magnification.
EpCAM, epithelial cell adhesion molecule; SEM, scanning
electron micrograph. Part A is reproduced with permission
from Sunitha Nagrath, PhD and part B is reproduced with
permission from Macmillan Publishers Ltd: Nature 2007;450:
1235–1239.
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vanced NSCLC, it was observed among patients who re-
ceived gemcitabine/cisplatin that those with low RRM1 mes-
senger RNA (mRNA) expression levels showed significantly
increased overall survival (OS) compared with patients who
had high RRM1 expression levels (13.7 months versus 3.6
months, p  0.009).20 However, RRM1 mRNA expression
level did not correlate with increased OS in patients who
received other gemcitabine-based chemotherapeutic regimens
in this trial. Results from a prospective phase II trial in
patients with advanced, unresectable NSCLC demonstrate
that tumors with low RRM1 gene expression respond signif-
icantly better to induction therapy with carboplatin and gem-
citabine than tumors with high levels of RRM1 expression
(p 0.002).6,17 In contrast, early results from a phase III trial
of gemcitabine/carboplatin versus gemcitabine alone demon-
strate no significant correlation between RRM1 expression
and survival among patients who are receiving carboplatin/
gemcitabine compared with those receiving gemcitabine
alone (6.7 months versus 5.1 months, p  0.28).21
Excision Repair Cross-Complementing Group 1
(ERCC1)
ERCC1 is an excision nuclease that participates in the
nucleotide excision repair process responsible for the repair
of platinum-induced damage to DNA.14,22 Preclinical studies
have shown that expression levels of ERCC1 mRNA directly
correlate with platinum resistance.22–25 At this time, it re-
mains unclear whether ERCC1 expression can be consistently
correlated with survival benefit from chemotherapy. In the
International Adjuvant Lung Trial, which compared the effi-
cacy of cisplatin-based adjuvant chemotherapy with postop-
erative observation in patients with completely resected stage
I to III NSCLC, a significant improvement in the 5-year
survival rate with cisplatin-based adjuvant chemotherapy
compared with observation was observed in the ERCC1
protein-negative but not ERCC1 protein-positive subgroup
(hazard ratio [HR] 0.65, p 0.002 versus HR 1.14, p
0.40; Figure 2).26 Nevertheless, in a phase III trial investigat-
ing the efficacy of ERCC1 mRNA expression-based customi-
zation of cisplatin-based chemotherapy in patients with stage
IV NSCLC, there was no significant difference in OS be-
tween the control arm (cisplatin/docetaxel) and the genotypic
arm (9.8 months versus 9.9 months, p  0.59), even though
patients in the genotypic arm were stratified such that those
with low ERCC1 expression received cisplatin/docetaxel and
patients with high ERCC1 expression received gemcitabine/
docetaxel.27
The presence of single nucleotide polymorphisms in
ERCC1 may account for inconsistency in the correlation
between ERCC1 expression and survival benefit from che-
motherapy.28,29 For example, a retrospective study of 130
patients with advanced NSCLC reported that patients with
codon 118 C/T or 118 T/T polymorphisms in ERCC1 had
significantly longer survival than patients with 118 C/C
polymorphisms after treatment with platinum-based chemo-
therapy (17.5 months versus 13.5 months, p  0.003).28
Evaluating the combined status of ERCC1 expression and
polymorphism may be a better predictor of response and
benefit from platinum-based chemotherapy.
RRM1 and ERCC1
Some studies have investigated the predictive value of
measuring both RRM1 and ERCC1 expression to guide se-
lection of chemotherapy for patients with NSCLC. For ex-
ample, a retrospective analysis of 100 patients from a larger
trial, which investigated the efficacy of frontline chemother-
apy in patients with advanced NSCLC, observed that low
levels of both RRM1 and ERCC1 mRNA expressions were
significant predictors of increased OS compared with high
levels after treatment with gemcitabine/cisplatin (median OS
not reached versus 6.8 months, p  0.02) but not gemcitab-
ine/cisplatin/vinorelbine (11.1 months versus 18.9 months, p
FIGURE 2. Kaplan-Meier curve estimates of survival probability from the International Adjuvant Lung Trial. A significant im-
provement in the 5-year survival rate with cisplatin-based adjuvant chemotherapy compared with observation (control) oc-
curred in the ERCC1-negative but not ERCC1-positive subgroup (HR  0.65 and p  0.002 versus HR  1.14 and p  0.4).
ERCC1, excision repair cross-complementing group; HR, hazard ratio; OS, overall survival. Reproduced with permission from
N Engl J Med 2006;355:983–991.
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0.29) or gemcitabine/vinorelbine followed by vinorelbine/ifosf-
amide (8.8 months versus 5.9 months, p  0.74).20 To investi-
gate the feasibility of chemotherapy selection based on RRM1
and ERCC1 gene expression, the prospective Molecular Anal-
yses–Directed Individualized Therapy for Advanced NSCLC
phase II study was conducted at a single institution.30 In
theory, patients with low ERCC1 levels were more likely to
receive benefit from platinum-based regimens, whereas pa-
tients with low RRM1 levels were more likely to receive
benefit from gemcitabine-based regimens. Thus, patients with
low RRM1 and ERCC1 levels were treated with gemcitabine/
carboplatin, and patients with high ERCC1 and RRM1 levels
were treated with docetaxel/vinorelbine. Patients with low
RRM1 and high ERCC1 levels were treated with gemcitabine/
docetaxel, and patients with high RRM1 and low ERCC1
levels were treated with docetaxel/carboplatin (Figure 3).
Results from this trial indicate that chemotherapy selection
based on tumor expression of RRM1 and ERCC1 seems
feasible and may confer patient benefit (response rate [RR],
44%; median OS, 13.3 months; and progression-free survival
[PFS], 6.6 months). These results are being confirmed in an
ongoing, multicenter, phase III trial of customized chemo-
therapy based on both RRM1 and ERCC1 expression in
patients with advanced NSCLC. The strategy of RRM1 and
ERCC1-directed customization of chemotherapy is also being
explored in the adjuvant setting in the Southwest Oncology
Group (SWOG) 0720 phase II trial, with the hope that
potential advances in biomarker development will translate
into broadly applicable and clinically meaningful improve-
ments in patient outcomes.
Thymidylate Synthase (TS)
TS is an enzyme involved in DNA biosynthesis that has
been investigated as a potential predictor of response to
pemetrexed.31 TS is responsible for maintaining intracellular
levels of thymidine, which is important for DNA synthesis
and repair.32 In preclinical studies, TS overexpression has
been correlated with resistance to pemetrexed.15,33 In addi-
tion, median TS mRNA expression seems to be significantly
higher in squamous cell carcinoma compared with adenocar-
cinoma (2.17 versus 1.16; p  0.0001), which suggests that
pemetrexed has decreased efficacy in patients with squamous
cell carcinoma compared with adenocarcinoma histologies.31
This hypothesis is supported by the results from a phase III
trial that compared the efficacy of cisplatin/gemcitabine with
cisplatin/pemetrexed in patients with advanced NSCLC.
Among the intent-to-treat population, the OS of patients who
received cisplatin/pemetrexed was similar to those who re-
ceived cisplatin/gemcitabine (10.3 months versus 10.3
months, HR  0.94).34 However, among patients with
nonsquamous histologies, cisplatin/pemetrexed significantly
improved OS compared with cisplatin/gemcitabine (11.8
months versus 10.4 months; p 0.005; Figure 4). In contrast,
patients with squamous cell carcinoma derived significantly
improved OS with cisplatin/gemcitabine compared with cis-
platin/pemetrexed (10.8 months versus 9.4 months; p 
0.05). Although these results are hypothesis generating and
provide evidence that the expression of TS in various tumor
histologies could be used to guide the use of pemetrexed,
prospective studies must be conducted to define the potential
role of TS as a predictive molecular marker.
Gene Expression Profiling
An increased understanding in the molecular biology
and the genetics of lung tumorigenesis has resulted in the
identification of prognostic or predictive gene expression
profiles that may inform treatment decisions. For example,
risk assessment models are being developed from gene ex-
pression profiles to predict the probability of tumor recur-
rence and potential for benefit from adjuvant chemotherapy.
Molecular signatures derived from composites of as few as
three to as many as 64 genes have been used to stratify
patients into high-risk and low-risk groups that differ in
survival.35–37 One study of 101 patients that developed a
five-gene signature predictor reported that patients with a
high-risk gene signature had a shorter OS than patients with
a low-risk gene signature (20 months versus 40 months; p 
0.001).36 Models predicting risk of tumor recurrence have
also been developed from diverse data sets, including a
genome-wide expression profile, a microRNA expression
profile, and an integrated profile of clinical factors and gene
expression.38–40 The lung metagene model based on gene
expression profiles was able to identify a subgroup of stage
IA patients at a high risk for recurrence.38 Validation using
clinical sample sets from two trials, the American College of
Surgical Oncologists Group Z0030 study (n  25) and the
Cancer and Leukemia Group B (CALGB) 9761 study (n 
84), also showed that the lung metagene model was a signif-
icantly more accurate predictor of tumor recurrence than
disease stage, tumor diameter, nodal status, age, sex, histo-
FIGURE 3. The phase II MADeIT trial selected chemother-
apy regimens on the basis of tumor expression levels of
ERCC1 and RRM1 in patients with advanced NSCLC. ERCC1,
excision repair cross-complementing group 1; MADeIT, Mo-
lecular Analyses–Directed Individualized Therapy for Ad-
vanced NSCLC; NSCLC, non-small cell lung cancer; RRM1,
ribonucleotide reductase subunit 1; RT-PCR, reverse-tran-
scriptase polymerase chain reaction.
West et al. Journal of Thoracic Oncology • Volume 4, Number 9, Supplement 2, September 2009
Copyright © 2009 by the International Association for the Study of Lung CancerS1032
logic classification, or smoking history (p 0.001; Figure 5).
By applying the lung metagene model to 68 patients with
stage IA disease, a subgroup of patients was identified who
had a high risk for recurrence and may benefit from adjuvant
chemotherapy. On the basis of these results, the CALGB
30506 phase III trial has been activated to evaluate whether
the lung metagene score can direct adjuvant chemotherapy
selection for patients with stage I NSCLC (expected enroll-
ment  1525 patients).
Ultimately, risk models from gene signatures may be
used to drive the selection of adjuvant chemotherapy. Using
risk assessment models, patients with resected tumors and
low-risk gene signatures could be spared additional cytotoxic
chemotherapy, whereas patients with resected tumors and
high-risk gene signatures would be given adjuvant chemo-
therapy.36 A recently reported study identified a 15-gene
expression profile that could classify patients with resected
stage IB or II NSCLC from the JBR.10 trial of vinorelbine/
cisplatin versus observation into groups with a high or low
risk for death.41,42 Adjuvant chemotherapy significantly re-
duced the risk of death for 67 high-risk patients (HR  0.33;
p  0.0005), but this benefit was not observed among the 66
low-risk patients (HR  3.67; p  0.0133).41 Furthermore,
the interaction between chemotherapy and gene expression
signature was highly significant (p  0.0001). Genomic
signatures are also being investigated for their ability to
predict sensitivity to individual and multidrug chemothera-
peutic regimens.16
To use gene expression-based classifiers in the clinical
setting, prospective trials will be needed to develop and
confirm the utility of predictive models for guiding treatment
selection. Gene expression profiling as a single mechanism
for model development may be inadequate, because the
addition of clinical covariates may improve predictive accu-
racy.40,43 It will also be necessary to determine the feasibility
of coordinating clinical and pathologic data collection across
multiple institutions. Despite significant challenges, the po-
tential for improving patient care and increasing survival
provides strong motivation for the continued development of
genomic tools for the treatment of patients with NSCLC.
MOLECULAR PREDICTORS OF RESPONSE TO
TARGETED THERAPY
Monoclonal antibodies and small-molecule tyrosine ki-
nase inhibitors (TKIs) targeting EGFR and the vascular
FIGURE 4. Kaplan-Meier OS curves for patients with nonsquamous and squamous histologies. In patients with nonsqua-
mous histologies, cisplatin/pemetrexed significantly improved OS compared with cisplatin/gemcitabine (11.8 months versus
10.4 months; p  0.005), whereas patients with squamous cell carcinoma derived significantly improved OS with cisplatin/
gemcitabine compared with cisplatin/pemetrexed (10.8 months versus 9.4 months; p  0.05). CG, cisplatin/gemcitabine; CP,
cisplatin/pemetrexed; HR, hazard ratio; OS, overall survival; SCC, squamous cell carcinoma. Reproduced with permission from
J Clin Oncol 2008;26:3543–3551.
FIGURE 5. Kaplan-Meier survival
curve estimates for the Duke Train-
ing Cohort from the lung met-
agene model and a model based
on combined clinical variables. The
lung metagene model more clearly
stratifies high-risk and low-risk pa-
tients with respect to survival when
compared with the clinical model.
Reproduced with permission from
N Engl J Med. 2006;355:570–580.
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endothelial growth factor have recently emerged as effective
agents for the treatment of patients with advanced NSCLC.44
A number of clinical characteristics have been associated
with response to EGFR TKIs, including female gender,45
Asian ethnicity,46,47 never-smoker history,47–49 and patients
with adenocarcinoma, bronchioloalveolar carcinoma (BAC),
or papillary histologies.50–53 However, it is important to note
that male smokers and patients with squamous cell carcinoma
may still derive benefit from EGFR TKIs despite low RRs.54
Clinical characteristics alone may be insufficient for selecting
patients to receive targeted therapy, and because of the
heterogeneity of lung cancer biology, individual tumors may
be diverse at the molecular level within clinically selected
patient populations. Therefore, tumor molecular characteris-
tics are also being investigated as potential predictors of
sensitivity or resistance to targeted agents.
Predictors of Sensitivity to EGFR Inhibitors
EGFR protein overexpression, increased gene copy
number, and gene mutations have all been examined as
potential biomarkers of response to EGFR inhibitors.
EGFR Mutations
Mutations in EGFR have been correlated with RRs
more than 70% in multiple prospective studies of patients
with EGFR mutations who received treatment with EGFR
TKIs, and increasing clinical evidence suggests that patients
with EGFR mutations may receive more benefit from EGFR
TKI therapies than patients with wild-type EGFR (Table
1).2,47,53,55–60 For example, in the ongoing, phase III trial,
Iressa Pan-Asian Study, gefitinib and carboplatin/paclitaxel
chemotherapy are being compared in never or light smokers
with adenocarcinoma, and recent reports indicate that the PFS
in the intent-to-treat population was significantly increased
among patients who received gefitinib compared with carbo-
platin/paclitaxel (HR  0.74, p  0.0001).47 When patient
outcomes were stratified by the presence or absence of EGFR
mutation, patients with EGFR mutations had significantly
longer PFS if they received gefitinib compared with chemo-
therapy (HR  0.48, p  0.0001), whereas patients without
EGFR mutations had significantly longer PFS if they received
chemotherapy compared with gefitinib (gefitinib HR  2.85,
p  0.0001). In addition, the preliminary HR for OS among
patients with EGFR mutations who received gefitinib was
0.78 compared with an HR of 1.38 for patients without EGFR
mutations who received gefitinib, which indicates that ge-
fitinib may be detrimental to patients without EGFR muta-
tions, even in a clinically defined subset of never or light
smokers of Asian ethnicity who would likely be selected for
early EGFR-TKI therapy in current oncology practice.
Different results were reported by the Iressa NSCLC
Trial Evaluating Response and Survival Against Taxotere
(INTEREST) trial, which compared the efficacy of gefitinib
and docetaxel in previously treated patients with NSCLC and
showed a lack of association between treatment with gefitinib
and OS when patients were stratified by EGFR mutations,
EGFR gene amplification, or EGFR protein expression.61,62 It
is unclear whether the second-line setting of the INTEREST
trial contributed to the lack of association between the treat-
ment with gefitinib and EGFR status because tissue samples
available for molecular analysis were most commonly ob-
tained before first-line chemotherapy. It is possible that dif-
ferential responses to EGFR inhibitors result from the diver-
sity of somatic EGFR mutations in patients with NSCLC. A
retrospective study that examined 3303 EGFR mutations
from 12,244 patients suggests that RRs to EGFR TKIs may
be specific to mutation type, EGFR exon, and presence of
dual mutations.63
EGFR Protein Overexpression
Compared with EGFR mutation status, EGFR protein
overexpression and increased EGFR gene copy number are
less consistent predictors of clinical benefit from EGFR-
targeted therapy, and ongoing clinical trials are attempting to
clarify the role of EGFR FISH and IHC testing in patient
selection. The First-Line Erbitux in Lung Cancer (FLEX)
trial (n  1125) investigated the efficacy of cisplatin and
vinorelbine with or without cetuximab in previously un-
treated patients with EGFR-positive (by IHC), advanced,
NSCLC, and showed significantly increased OS among pa-
tients who received cisplatin/vinorelbine and cetuximab com-
pared with cisplatin/vinorelbine alone; these results suggest
the potential benefit of cetuximab for preselected patients
(11.3 months versus 10.1 months; p  0.044).64 In the FLEX
trial, EGFR-positive NSCLC was defined as having 1 or more
positively stained tumor cells by IHC. In contrast, the BMS-
099 trial (n  676) compared the efficacy of carboplatin and
a taxane with or without cetuximab in previously untreated
patients with advanced NSCLC and showed that in this
otherwise unselected population, the addition of cetuximab
did not significantly improve OS (9.7 months versus 8.4
months; p  0.17) or PFS (4.4 months versus 4.2 months;
p  0.24).65 On the basis of the results from FLEX and
BMS-099, cetuximab in combination with chemotherapy is
an increasingly considered option for the frontline treatment
of select patients with NSCLC, and this recommendation was
recently added to the National Comprehensive Cancer Net-
work Clinical Practice Guidelines in Oncology.44
TABLE 1. Prospective Studies of Patients with EGFR





Mutations Agent RR (%) TTP (mo)
Paz-Ares et al.55 1047 127 Erlotinib 82 13.3
Miller et al.53,a 81 18 Erlotinib 83 13
Inoue et al.2 99 16 Gefitinib 75 9.7
Sutani et al.56 100 38 Gefitinib 78 9.4
Asahina et al.57 82 16 Gefitinib 75 8.9
ONCOBELL58 37 24 Gefitinib 71 3.8
Sunaga et al.59 33 21 Gefitinib 76 12.9
IPASS47 1217 132 Gefitinib 71 NR
Tamura et al.60 118 32 Gefitinib 75 11.5
a Patients with bronchioloalveolar carcinoma.
EGFR, epidermal growth factor receptor; IPASS, Iressa Pan-Asian Study; NR, not
reported; RR, response rate; TKI, tyrosine kinase inhibitor; TTP, time to progression.
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EGFR Gene Copy Number
High EGFR gene copy number has also been associated
with benefit from treatment with EGFR inhibitors (Table
2),53,58,66–71 but the predictive significance of EGFR FISH
testing has yet to be confirmed in a prospective phase III trial.
A subset analysis (n  159) of the BR.21 trial investigating
the efficacy of erlotinib versus placebo in patients with
previously treated NSCLC reported that significant survival
benefit from erlotinib was correlated with high but not low
EGFR copy number (p  0.004 versus p  0.353).67 Simi-
larly, the phase II SWOG 0342 trial of sequential or concur-
rent paclitaxel and carboplatin with cetuximab in patients
with advanced NSCLC showed significantly increased OS
among patients with high but not low EGFR gene copy
number (15 months versus 7 months; p  0.046).71 The
prospective ONCOBELL phase II trial (n  36) evaluated
gefitinib sensitivity in patients with advanced NSCLC who
had never smoked, had increased EGFR gene copy number,
or activated Akt.58 Compared with patients with low EGFR
gene copy number, patients with high EGFR gene copy
number had significantly increased time to progression (7.6
months versus 2.7 months; p  0.02) and a trend toward
longer OS that did not reach statistical significance (not
reached versus 7.4 months; p  0.3). EGFR gene copy
number has also been analyzed in patients (n  101) with
BAC or adenocarcinoma with BAC subtype in a phase II trial
of erlotinib.53 Patients with high EGFR gene copy number
had a significantly increased PFS compared with those with
low EGFR gene copy number (9 months versus 2 months;
p  0.01); however, the increase in OS among patients with
high EGFR gene copy number did not reach statistical sig-
nificance (25 months versus 16 months; p  0.38). Contrast-
ing results were reported from the INVITE trial, which
compared the efficacy of gefitinib with that of vinorelbine in
elderly patients (70 years of age; n  196) with advanced
NSCLC.72 In this trial, patients with high EGFR copy number
who received treatment with gefitinib had a nonsignificant
trend toward poorer PFS and OS compared with patients who
had low EGFR gene copy number and received treatment
with gefitinib (HR for PFS  1.31; HR for OS  1.61).
Conversely, patients with high EGFR gene copy number who
received vinorelbine had a nonsignificant trend toward im-
proved PFS and OS compared with patients who had low
EGFR gene copy number (HR for PFS  0.77; HR for OS 
0.52). Further investigation will be required to determine the
predictive value of EGFR copy number in selecting targeted
therapy for patients with NSCLC. New, adaptive, trial de-
signs, such as the one used in the Biomarker-based Ap-
proaches of Targeted Therapy for Lung Cancer Elimination
(BATTLE) trial, may facilitate and accelerate the validation
of molecular biomarkers for clinical practice (Figure 6).73 In
the BATTLE trial, patients’ biomarker profiles are used to
select treatment, and patients are randomized to receive one
of the four treatments: sorafenib, erlotinib, vandetanib, or
erlotinib/bexarotene. Using an adaptive randomization trial
design, patients are more likely to be randomized to an
effective, targeted-therapy arm.
Predictors of Resistance to EGFR Inhibitors
Gene mutations have also emerged as potential predic-
tors of resistance to EGFR inhibitors for patients with
NSCLC. In particular, mutations in the KRAS gene were
reported to confer resistance to gefitinib or erlotinib ther-
apy.74 Clinical trials demonstrate that patients with mutant
KRAS are unlikely to demonstrate a significant response to
EGFR inhibitors, when compared with patients with wild-
type KRAS; however, it is unclear whether poor response to
therapy correlates with shorter survival (Table 3).53,61,67,75–78
FIGURE 6. Trial schema for the BATTLE trial. BATTLE, Bi-
omarker-Based Approaches of Targeted Therapy for Lung
Cancer Elimination.
TABLE 2. Effect of EGFR Gene Copy Number on Response to EGFR Inhibitors
Trial No. of Pts Agent
RR (%) OS (mo)
FISH FISH FISH FISH
TRIBUTE66 245 Erlotinib 12 22 12 10
Miller et al.53,a 76 Erlotinib 43 13 25 16
BR.2167 91 Erlotinib 21 5 11 6
Bell et al.68 40 Gefitinib 29 15 12 9
Cappuzzo et al.69 102 Gefitinib 36 3 19 7
ONCOBELL58,b 36 Gefitinib 68 9 NR 7
iTARGET70,b 29 Gefitinib 50 43 NR
SWOG 034271,b 76 Cetuximab 45 26 15 7
a Chromogenic in situ hybridization analysis in bronchioloalveolar carcinoma.
b Prospective analysis.
EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization; NR, not reported; OS, overall survival; RR, response
rate; SWOG, Southwest Oncology Group.
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In a retrospective study, patients with advanced NSCLC (n
73) and KRAS mutation who were treated with gefitinib or
erlotinib experienced a significantly shorter time to progres-
sion (1.7 months versus 2.9 months; p  0.0025), but not a
significantly shorter OS (5.0 months versus 9.4 months; p 
0.62), when compared with patients with wild-type KRAS.75
In a prospective trial of patients (n  101) with BAC or
adenocarcinoma with BAC subtype who were treated with
erlotinib, no patient with a KRAS mutation met Response
Evaluation Criteria in Solid Tumors, when compared with
patients with wild-type KRAS who had an RR of 32% (p 
0.01).53 A plot of best response from indicator lesions ac-
cording to Response Evaluation Criteria in Solid Tumors
shows that some patients with KRAS mutations achieved a
minor response or stable disease (Figure 7), which indicates
that some patients with KRAS mutations may receive a
modest survival benefit from erlotinib. Despite the lack of
response to erlotinib among patients with KRAS mutations,
the shorter PFS (4 months versus 5 months; p 0.25) and OS
(13 months versus 21 months; p  0.3) among patients with
KRAS mutations did not reach statistical significance, when
compared with patients without KRAS mutations.
A retrospective study of patients (n  206) from the
BR.21 trial (which investigated the efficacy of erlotinib
versus placebo) reported that KRAS mutation status did not
significantly impact survival for patients treated with erlotinib
(p  0.09).67 Similarly, a subgroup analysis of patients (n 
114) in the INTEREST trial, which evaluated the efficacy of
gefitinib versus docetaxel, reported that the p value for OS for
interaction between KRAS mutation status and treatment was
not significant (p  0.51).61 In contrast, a retrospective
review of five clinical trials performed in Europe and the
United States involving patients with NSCLC, who were
treated with erlotinib or gefitinib, suggests that KRAS muta-
tions are associated with resistance to EGFR-TKI therapy, at
least when defined by response.76 Additional prospective
trials are needed to clarify the role of KRAS mutations in
predicting benefit from EGFR-inhibitor therapy for patients
with NSCLC.
SUMMARY AND CONCLUSION
Molecular markers such as ERCC1, RRM1, and TS, as
well as gene expression profiling may predict response to
chemotherapy. Similarly, EGFR protein overexpression, in-
creased EGFR gene copy number, and mutations in EGFR
and KRAS may predict response to EGFR inhibitors. The
identification of molecular biomarkers that predict response
to chemotherapy and targeted therapy has the potential to
transform the treatment paradigm of NSCLC from relying on
clinical characteristics such as tumor stage, performance
status, and smoking history to utilizing analyses of molecular
characteristics of individual patients for therapeutic decision
making. Additional prospective trials and new clinical trial
designs are urgently needed to further define and validate the
potential role of these and other novel biomarkers in the
treatment of NSCLC.
FIGURE 7. Plot of best response
of indicator lesions according to
RECIST criteria in patients with BAC
and patients with adenocarcinoma
with BAC subtype who received
erlotinib. BAC, bronchioloalveolar
carcinoma; CISH, chromogenic in
situ hybridization; EGFR, epidermal
growth factor receptor; RECIST,
Response Evaluation Criteria in
Solid Tumors. Reproduced with
permission from J Clin Oncol 2008;
26:1472–1478.
TABLE 3. KRAS Mutations and Resistance to EGFR Inhibitors
Trial No. of Pts Agent
RR (%) OS (mo)
Wild-Type KRAS Mutant KRAS Wild-Type KRAS Mutant KRAS
Miller et al.53,a 101 Erlotinib 32 0 21 13
BR.21.67 206 Erlotinib 10.2 5 7.5 3.7
Massarelli et al.75 70 Erlotinib or Gefitinib 10 0 9.4 5
Jackman et al.76 116 Erlotinib or Gefitinib 5 0 11.8 13
INTEREST61 275 Gefitinib 10 0 7.5 7.8
BMS-09977 202 Cetuximab 33 31 10 17
a Patients with bronchioloalveolar carcinoma.
INTEREST, Iressa NSCLC Trial Evaluating Response and Survival Against Taxotere; EGFR, epidermal growth factor receptor; OS, overall survival; RR, response rate.
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DISCUSSION
Howard West, MD
I think that we are moving away from treating NSCLC
as a static entity that has been managed the same way for 10
years, to an era where we can personalize treatments and do
better. New methods are being developed to more accurately
detect molecular biomarkers. What types of developments or
changes are happening in the field of biomarker detection
technology?
Lecia Sequist, MD, MPH
In general, I think that more modern techniques are
moving away from looking at the narrow focus of a single
gene abnormality to a more global type of analysis of what
the functional implication of a cell’s full genetic makeup is.
I think that is a good trend. From a clinician’s standpoint, I
think the most clinically useful molecular markers will be
those that are clearly paired with some sort of trigger of what
to do—a treatment recommendation. So if you see this
marker, do this, and if you don’t see this marker, do that. I
think those kinds of markers will move forward into practice
the quickest. The significant obstacle to all of these tech-
niques is the availability of tumor tissue, especially in lung
cancer, where invasive biopsies can be risky for patients.
Howard West, MD
Can you update us on some of the ongoing trials
looking at biomarkers?
Roy S. Herbst, MD, PhD
We have the BATTLE program; the idea behind it is
that you can only do so much with clinical characteristics.
We’re getting biopsies on all of our patients, and we do an
adaptive randomization, where patients are more likely to be
randomized to the arm which has shown benefit for prior
patients with that particular marker profile and a given drug.
There are rules to shut down or suspend groups early if we’re
not seeing any activity. Basically, here’s the way we do it: an
umbrella protocol, equal and then adaptive randomization,
and treatment with four drugs. I can tell you we’re now
developing our BATTLE 2 and 3 programs because we’ve
been very happy with this framework. Even if we’re com-
pletely wrong about these agents and our 11-marker profile,
we’re generating a great deal of information for exploration
and discovery in the future.
Antoinette Wozniak, MD
There is actually a trial that is about to start in SWOG.
SWOG 0720 is a feasibility study in patients with stage I
NSCLC and resected tumors that were larger than 2 cm. They
are going to use AQUA technology [HistoRx; New Haven,
CT] to look at ERCC1 and RRM1 protein expression. If
patients have high expression of both ERCC1 and RRM1,
they get observed and will probably not get adjuvant chemo-
therapy. If patients have low expression of both ERCC1 and
RRM1, they are going to get adjuvant chemotherapy with
cisplatin/gemcitabine.
David Harpole, MD
We’re excited about the activation of CALGB 30506.
We’re expecting to randomize about 1500 patients. Our goal
is to demonstrate a survival advantage for patients receiving
adjuvant chemotherapy compared with observation and to
validate whether the lung metagene model is prognostic for
survival in stage I patients. It’s going to be especially inter-
esting to see whether there is a highly significant survival
benefit for patients treated with adjuvant chemotherapy who
have high-risk lung metagene scores. At the end, there’s
going to be 600 patients for whom we’re going to have
complete array data as well as chemotherapy data. So I think
the opportunity is in this data set to learn a whole lot about
these things in the future, which is going to be great for
investigators.
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